Royalty Pharma director awarded 4,545 RSUs

Royalty Pharma plc director David C. Hodgson reported an acquisition of 4,545 restricted stock units linked to Class A ordinary shares as equity compensation.

Rhea-AI Filing Summary

Royalty Pharma plc director David C. Hodgson reported an acquisition of 4,545 restricted stock units linked to Class A ordinary shares as equity compensation. The award was granted under the company’s 2020 Independent Director Equity Incentive Plan and is scheduled to vest 100% on the earlier of one year from grant or the next annual shareholder meeting. The restricted stock units are held solely for the benefit of General Atlantic Service Company, L.P., and Hodgson disclaims beneficial ownership of the underlying shares. Following this grant, 37,873 Class A ordinary shares are reported as directly held.

Insider Trade Summary

Grant/Award: 4,545 shares

Grant/Award 1 txn

Insider HODGSON DAVID C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	$0.00

Holdings After Transaction: Class A Ordinary Shares — 37,873 shares (Direct)

Footnotes (1)

1. F1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the Reporting Person are held by him solely for the benefit of General Atlantic Service Company, L.P. The Reporting Person disclaims beneficial ownership of the restricted stock units in the underlying shares.

Key Figures

Restricted stock units granted: 4,545 units Reported shares after grant: 37,873 Class A ordinary shares Grant price per share: $0.0000 per share +1 more

4 metrics

Restricted stock units granted 4,545 units Award under 2020 Independent Director Equity Incentive Plan

Reported shares after grant 37,873 Class A ordinary shares Holdings following the transaction

Grant price per share $0.0000 per share Reported transaction price on Form 4

Vesting schedule 100% cliff vesting Earlier of one-year anniversary or next annual shareholder meeting

Key Terms

restricted stock units, 2020 Independent Director Equity Incentive Plan, beneficial ownership, annual meeting of the Issuer's shareholders

4 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Independent Director Equity Incentive Plan financial

"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of the restricted stock units in the underlying shares."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

annual meeting of the Issuer's shareholders financial

"the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Royalty Pharma (RPRX) report for David C. Hodgson?

Royalty Pharma reported that director David C. Hodgson received 4,545 restricted stock units as an equity grant. These units relate to Class A ordinary shares and were awarded at no cash cost under the 2020 Independent Director Equity Incentive Plan.

When do David C. Hodgson’s new Royalty Pharma (RPRX) restricted stock units vest?

The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting. Vesting also depends on the terms of the 2020 Independent Director Equity Incentive Plan and the related award agreement.

Who ultimately benefits from David C. Hodgson’s Royalty Pharma (RPRX) restricted stock units?

The filing states that Hodgson holds the restricted stock units solely for the benefit of General Atlantic Service Company, L.P. He disclaims beneficial ownership of the underlying shares, meaning economic benefits are attributed to that entity rather than to him personally.

How many Royalty Pharma (RPRX) shares are reported after David C. Hodgson’s grant?

After the grant, the filing shows 37,873 Class A ordinary shares reported as directly held. This figure reflects the updated position following the award of 4,545 restricted stock units linked to the company’s shares.

Is David C. Hodgson’s Royalty Pharma (RPRX) transaction an open‑market purchase or sale?

No, the transaction is classified as a grant or award acquisition, not an open‑market trade. The restricted stock units were issued as compensation under the 2020 Independent Director Equity Incentive Plan at a reported price of $0.0000 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HODGSON DAVID C

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/05/2026		A		4,545(1)	A	$0	37,873	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the Reporting Person are held by him solely for the benefit of General Atlantic Service Company, L.P. The Reporting Person disclaims beneficial ownership of the restricted stock units in the underlying shares.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person holds limited partnership interests in RPI US Partners 2019, LP exchangeable into 79,476 Class A Ordinary Shares.

	/s/ Sean Weisberg, as Attorney-in-Fact for David C. Hodgson	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)